These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 26423184)

  • 21. Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials.
    Grimm M; Han J; Weaver C; Griffin P; Schulteis CT; Dong H; Malloy J
    Postgrad Med; 2013 May; 125(3):47-57. PubMed ID: 23748506
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative efficacy of exenatide versus insulin glargine on glycemic control in type 2 diabetes mellitus patients inadequately treated with metformin monotherapy.
    Karagianni P; Polyzos SA; Kartali N; Zografou I; Sambanis C
    Adv Med Sci; 2013; 58(1):38-43. PubMed ID: 23640946
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A systematic review and meta-analysis of the efficacy of lixisenatide in the treatment of patients with type 2 diabetes.
    Schmidt LJ; Habacher W; Augustin T; Krahulec E; Semlitsch T
    Diabetes Obes Metab; 2014 Sep; 16(9):769-79. PubMed ID: 24476092
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of once daily GLP-1 receptor agonist lixisenatide compared to bolus insulin both in combination with basal insulin for the treatment of patients with type 2 diabetes in Norway.
    Huetson P; Palmer JL; Levorsen A; Fournier M; Germe M; McLeod E
    J Med Econ; 2015; 18(8):573-85. PubMed ID: 25853868
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients.
    Derosa G; Maffioli P; Ferrari I; Palumbo I; Randazzo S; D'Angelo A; Cicero AF
    J Pharm Pharm Sci; 2010; 13(3):378-90. PubMed ID: 21092710
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone.
    Derosa G; Fogari E; D'Angelo A; Cicero AF; Salvadeo SA; Ragonesi PD; Ferrari I; Gravina A; Fassi R; Fogari R
    J Clin Pharm Ther; 2007 Jun; 32(3):261-8. PubMed ID: 17489878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lixisenatide Reduces Chylomicron Triacylglycerol by Increased Clearance.
    Whyte MB; Shojaee-Moradie F; Sharaf SE; Jackson NC; Fielding B; Hovorka R; Mendis J; Russell-Jones D; Umpleby AM
    J Clin Endocrinol Metab; 2019 Feb; 104(2):359-368. PubMed ID: 30215735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Once-weekly exenatide as a treatment for Type 2 diabetes.
    Schauerhamer MB; Gurgle H; McAdam-Marx C
    Expert Rev Cardiovasc Ther; 2015 Jun; 13(6):611-26. PubMed ID: 26000560
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Obesity and Type 2 diabetes mellitus.
    Wilding J
    Diabet Med; 2000 May; 17(5):400-2. PubMed ID: 10872543
    [No Abstract]   [Full Text] [Related]  

  • 30. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.
    Robinson AC; Burke J; Robinson S; Johnston DG; Elkeles RS
    Diabetes Care; 1998 May; 21(5):701-5. PubMed ID: 9589227
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The influence of 6-months treatment with exenatide on type 2 diabetes mellitus compensation, anthropometric and biochemical parameters].
    Roubícek T; Mráz M; Bártlová M; Kaválková P; Haluzíková D; Trachta P; Housová J; Matoulek M; Svacina S; Haluzík M
    Vnitr Lek; 2010 Jan; 56(1):15-20. PubMed ID: 20184107
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [An overweight diabetic does not tolerate metformin. Insulin sensitizer can be prescribed alone, too].
    MMW Fortschr Med; 2003 Dec; 145(49):58. PubMed ID: 14963999
    [No Abstract]   [Full Text] [Related]  

  • 33. Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes.
    Schnabel CA; Wintle M; Kolterman O
    Vasc Health Risk Manag; 2006; 2(1):69-77. PubMed ID: 17319471
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lixisenatide as add-on to oral anti-diabetic therapy: an effective treatment for glycaemic control with body weight benefits in type 2 diabetes.
    Raccah D; Gourdy P; Sagnard L; Ceriello A
    Diabetes Metab Res Rev; 2014 Nov; 30(8):742-8. PubMed ID: 24687427
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia).
    Yu Pan C; Han P; Liu X; Yan S; Feng P; Zhou Z; Lv X; Tian H; Jin Kui Y; Su B; Shang S; Niemoeller E
    Diabetes Metab Res Rev; 2014 Nov; 30(8):726-35. PubMed ID: 24639432
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Therapy with incretin mimetic exenatide. Soon HbA1c value and weight decrease permanently].
    MMW Fortschr Med; 2006 Sep; 148(37):55. PubMed ID: 17036908
    [No Abstract]   [Full Text] [Related]  

  • 37. [Future perspectives in the treatment of type 2 diabetes].
    Keller U
    Wien Klin Wochenschr; 2004 Apr; 116(7-8):213-4. PubMed ID: 15143858
    [No Abstract]   [Full Text] [Related]  

  • 38. Diurnal glucose exposure profiles of patients treated with lixisenatide before breakfast or the main meal of the day: An analysis using continuous glucose monitoring.
    Bergenstal RM; Strock E; Mazze R; Powers MA; Monk AM; Richter S; Souhami E; Ahrén B
    Diabetes Metab Res Rev; 2017 May; 33(4):. PubMed ID: 28032465
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Weight reducing and glucose reducing effects of liraglutide treatment for patients with type 2 diabetes].
    Penninga E; Færch K; Almdal T
    Ugeskr Laeger; 2011 Jun; 173(26):1863-9. PubMed ID: 21712007
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lixisenatide: A New Daily GLP-1 Agonist for Type 2 Diabetes Management.
    McCarty D; Coleman M; Boland CL
    Ann Pharmacother; 2017 May; 51(5):401-409. PubMed ID: 28133970
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.